Kalaris Therapeutics, Inc. SEC filings KLRS
Kalaris Therapeutics, Inc. has 699 filings in SEC EDGAR's recent list, going back to Oct 2, 2018. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Apr 13, 2026 | — |
| EFFECT | Filing | Apr 13, 2026 | — |
| CORRESP | Letter to the SEC | Apr 9, 2026 | — |
| CORRESP | Letter to the SEC | Apr 9, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 8, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 8, 2026 | — |
| SEC STAFF LETTER | Filing | Feb 10, 2025 | — |
| EFFECT | Filing | Feb 10, 2025 | — |
| CORRESP | Letter to the SEC | Feb 6, 2025 | — |
| CORRESP | Letter to the SEC | Feb 3, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 28, 2025 | — |
| CORRESP | Letter to the SEC | Jan 17, 2025 | — |
| 425 | Filing | Jan 15, 2025 | — |
| 425 | Filing | Jan 10, 2025 | — |
| 425 | Filing | Jan 10, 2025 | — |
| SEC STAFF LETTER | Filing | Jan 7, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 6, 2025 | — |
| 425 | Filing | Dec 20, 2024 | — |
| 425 | Filing | Dec 9, 2024 | — |
| 425 | Filing | Nov 8, 2024 | — |
| 425 | Filing | Nov 8, 2024 | — |
| 425 | Filing | Nov 8, 2024 | — |
| 425 | Filing | Nov 8, 2024 | — |
| 425 | Filing | Nov 8, 2024 | — |
| 425 | Filing | Nov 8, 2024 | — |
| RW | Filing | Feb 15, 2024 | — |
| DEL AM | Filing | Feb 16, 2023 | — |
| EFFECT | Filing | Feb 28, 2022 | — |
| POSASR | Posasr (amendment no. 1) | Feb 10, 2022 | — |
| EFFECT | Filing | Jul 29, 2020 | — |
| CERT | Filing | Jul 29, 2020 | — |
| 8-A12B/A | Filing | Jul 29, 2020 | — |
| CORRESP | Letter to the SEC | Jul 28, 2020 | — |
| 8-A12B | Filing | Jul 27, 2020 | — |
| CORRESP | Letter to the SEC | Jul 27, 2020 | — |
| CORRESP | Letter to the SEC | Jul 27, 2020 | — |
| CORRESP | Letter to the SEC | Jul 27, 2020 | — |
| UPLOAD | Letter from the SEC | Jul 24, 2020 | — |
| CORRESP | Letter to the SEC | Jul 23, 2020 | — |
| CORRESP | Letter to the SEC | Jul 20, 2020 | — |
| CORRESP | Letter to the SEC | Jul 17, 2020 | — |
| UPLOAD | Letter from the SEC | Jul 14, 2020 | — |
| CORRESP | Letter to the SEC | Jul 6, 2020 | — |
| UPLOAD | Letter from the SEC | Jun 30, 2020 | — |
| DRS | Filing | Jun 3, 2020 | — |
| D | Filing | May 22, 2019 | — |
| D | Filing | Oct 2, 2018 | — |
Showing 47 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- KLRS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Berkeley Heights, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1754068
- Former names
- Allovir, Inc. (until Mar 12, 2025); ViraCyte, Inc. (until Oct 2, 2018)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.